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Abstract: Proteins therapy is of great importance in the treatment of protein deﬁciency disease. Most
human diseases are related to the malfunctioning of one or more proteins. The most eﬀective and direct ap-
proach is protein therapy, which delivers the proteins into the target cell to replace the dysfunction protein and
maintain the balance of organism. However, clinical application is frequently hampered by various biological
barriers to their successful delivery. This review aims to discuss the recent advances about microparticles and
nanoparticles fabricated using micro and nanotechnology for intracellular delivery therapy protein and give
some suggestions about the promising delivery system.
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Introduction
Organisms contain thousands of proteins, which per-
form a vital role in growthdevelopment, metabolism
regulation and disease therapy. These proteins take ef-
fect in organism and resist the outside unfavorable fac-
tors. Therefore, those speciﬁc proteins have shown to
be a suitable target for drug research and development
(R&D). The Pharmaceutical Research and Manufac-
turers of America’s (PhRMA) listed 66 protein drugs
in 633 new biotechnology medicines relating to more
than 100 diseases in 2008, including virus infectious,
cancer and autoimmune diseases [1]. The drug target
for chemical compounds is not currently certain and the
non-speciﬁc interaction between the compounds and
unexpected proteins may cause intense side-eﬀects on
patients in clinical trials. Hence, protein therapy is con-
sidered as the most eﬀective and direct approach for the
dysfunctional protein disease.
Protein drugs gradually become the major in future
and thus play a critical role in the process of mod-
ern drug design. Although it has a broad application
prospect, the protein therapeutic potential and clinical
application is frequently hampered by various biologi-
cal barriers [2].
In contrast to injecting to human body directly, the
protein drug must overcome several biological barriers.
For example, protein delivery in the bloodstream need
avoiding kidney ﬁltration, uptake by phagocytes, ag-
gregation with serum proteins, and degradation by en-
dogenous nucleases [3]. In the bloodstream, phagocytes
cells such as monocytes and macrophages remove for-
eign material from the body to protect against infection
by fungi, bacteria and also certain therapeutic protein
complexes. Also, it is another challenge that protein
drug need get through the bloodstream and the vascu-
lar endothelial barriers. Protein drugs can not be al-
lowed the entry the certain tissues including the liver,
spleens, and some tumors until they are cleared from
the body [4]. Moreover, having been taken up by the
target cell, protein drugs must escape from the endo-
some to cytoplasm immediately in case they may de-
grade in decreasing pH and various hydrolytic enzymes
from lysosome [5]. Finally, protein must be released
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from the carrier if formulated with delivery agents.
In order to eﬀective protein therapywe need an ef-
fective delivery system to deliver the protein. And the
future delivery system must be safer and can also take
account of the barriers in organism. For these reasons
above, this review aims to present on-going research
on protein drug delivery system and serve to update
readers regarding new developments in protein delivery




Although most studies use biocompatible materials
to delivery the protein drugs, some researches reported
systemic delivery vehicles containing cell-penetration
peptides (CPPs) liked to the target protein for eﬀec-
tive transduction. The transactivator of transcription
(TAT) was a prototypical example of a cell-penetrating
peptide. In 1988, Frankel and Pabo [6] and Green and
Lowenstein [7] independently discovered that the trans-
activator of transcription (TAT) protein separated from
the Human Immunodeﬁciency Virus can penetrate cells
and activate the viral genome replication. The pro-
tein modiﬁed by TAT peptide can enter cells eﬃciently
while non-conjugated proteins were notable in the incu-
bation media rather than in cells [8]. Sun et al (2009)
has fused apoptin (a tumor speciﬁc killing protein) to
the transduction domain named protein transduction
domain 4 (PTD4), which is 11-amino acid sequence.
It has shown to delivery proteins across the cellular
membrane in a very eﬃcient way [9]. The data showed
that PTD4-apoptin protein was delivered across cellu-
lar membranes and the fused apoptin protein can sig-
niﬁcantly inhibited tumor growth in vivo [10].
The cell-penetration peptides can also help fusion
protein enter into the target cell, mainly due to the
speciﬁc electrostatic interaction and conﬁrmation. The
speciﬁc amino acid residues of cell-penetration peptide
may interact with the plasma membranes by strongly
electric complementation. Substitution of any basic
residue of TAT with neutral amino acid may restrain
the interaction with membranes, implying the charge
of TAT is necessary for cellular uptake [11]. Further-
more, the speciﬁc binding receptor on the surface of
target cells can also induce membrane deformation for
cellular delivery [12].
However, protein native conﬁrmation may change in
the process of protein modiﬁed and intracorporeal cir-
culation, which may induce the non-speciﬁc immunity.
So the stability, side eﬀect and nonspeciﬁc immuno-
genicity need to be taken into account for fusion protein
therapeutic treatment of human disease.
Micropaticles
Generally, micropaticles are deﬁned as particles be-
tween 1 and 1000 μm. Microparticle vesicles have stud-
ies extensively with many diﬀerent materials and poly-
mers since ﬁrst designed in the early seventies. These
diﬀerent formulations of micropaticles can resist de-
grading by enzyme and prolong protein’s life in vivo.
The following examples present various micropaticles
designed for protecting the protein drug.
Ploy (lactic-co-glcolic acid) (PLGA) can provided
sustained delivery of active VGEF (vascular endothe-
lial growth factor) in vivo for more than a month after
transplant [13]. One month after treatment an increase
in angiogenesis (small caliber caveolin-1 positive ves-
sels) and arteriogenesis (α-SMA-positive vessels) was
observed in animals treated with VEGF microparti-
cles, but not in free-VEGF groups. It has demon-
strated that the use of microparticles can protect the
activity of protein that can be easily and safely de-
liver to targets. Furthermore, other researchers pay
more focus on the sustained-release of micropaticles,
because sustained-release technology can reduce dosing
frequency, maximizing the eﬃcacy and reduce poor pa-
tient compliance [14]. Using the 10% PEG with PLGA
microparticles (MP), 45% of loading BSA was contin-
uously released during 4 week [15]. Similarly, a new
sustained-release amylopectin microsphere coated with
polylactide-coglycolide can maintain the human growth
hormone (hGH) above the baseline for at least 14 days
[16]. The data suggest longer-term trials in adults with
injection frequencies of no more than once every 2-3
weeks. Moreover, for tissue regeneration therapy, the
sustained-release microparticles can preciously regulate
the stem cell growth and development. Microparticles,
within aggregates of pluripotent stem cell (PSCs), can
stably control the spatial diﬀerentiation of stem cell
[17]. In general, these above strategies of micropar-
ticles proved to be of considerable potential values to
clinical use.
Unfortunately, although sustained-release micropati-
cles can reduce the dosing frequency and increasing pa-
tient compliance, there are very few microparticle deliv-
ery formulations approved for clinical use [18]. Several
problems such as initial burst release and denaturation
of entrapped proteins have prevented the realization of
commercially viable products. The microparticles uti-
lize various emulsions in formation processes. Protein
may happen to denature after contacting the water/oil
interface. So the mostly important issue is that the ma-
terials of microparticles need to easily incorpotate with
protein and maintain the native the conformation both
in preparation and in preserve.
Our lab has invented aqueous-aqueous emulsion
formed to encapsulate proteins into dextran micropar-
ticles [19-21] and further encapsulated into PLGA mi-
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croparticles [21]. Erythropoietin (EPO) is a recombi-
nant protein drug which is used to treat aplastic ane-
mia. But EPO in vivo were likely to aggregate and
cause the protein denaturation, which may increase
heart problems and even increase mortality in chronic
kidney disease patients [22]. But our aqueous-aqueous
emulsion can provide friendly environment for protein
drug because protein can not contact the hydrophobic
interface. The result showed EPO can release from the
composite PLGA microspheres with normal biological
activity without signiﬁcant aggregation (<2%). Mean-
while, the near zero-order release without a signiﬁcant
initial burst (<20% at the ﬁrst day) was achieved using
our aqueous-aqueous emulsion.
Looking at the various formulation materials and
preparation methods, the design of microparticle DDSs
should be considered compatibility with the protein
drug as well as the host. To reduce negative side-eﬀects
and unwarranted interaction with the host, researchers
should also opt for safer materials that can not inﬂu-
ence the protein structure, stability and other prop-
erties. However, largely-sized microparticles can not
be allowed the entry the target cell and also encounter
other barriers such as the blood-brain barrier. Thus,
nanoparticles might appear to overcome the biological
barriers.
Nanoparticles
Nanoparticle(NP) is a rapidly expanding area, in-
cluding the development of materials in the 5 to 1000
nm size range. The protein is entrapped, encapsulated
in the NP depending upon the method of preparation.
Owing to submicron in size, NPs are small enough to
avoid reticuloendothelial and phagocytic clearance. So
they can penetrate deep into tissues through ﬁne cap-
illaries and are easily taken up eﬃciently by the tar-
get cells [23]. Also they can overcome the barriers and
have excellent biocompatibility in contrast to larger mi-
croparticles.
This review focuses on intracellular delivery of thera-
peutic agents, so we compare various types of nanopar-
ticles, which have merits and demerits respectively (Ta-
ble 1). The main reason of demerit is that these for-
mulations do not overcome our biologic barriers totally.
The nanoparticles should be designed not only for pro-
tein entrapment, but also for good therapeutic eﬀect.
So it is extremely necessary to understand more mecha-
nisms of intracellular delivery before designing. Figure
1 shows the steps detailing the endocytosis mechanism.
Following their uptake, nanoparticles begin intracellu-
lar traﬃcking. Firstly they are transported to endo-
somes, which fuse with lysosomes subsequently. After
that, nanoparticles release from lysosomes into the cy-
toplasm, and diﬀuse to the therapeutic target, such as
nucleus and other organelles. In the whole process, the
biggest challenge is how nanoparticles escape the endo-
lysomes and enter the cytoplasm. Varkouli reviewed
advanced mechanisms of endosomal escape, which in-
cluded pore formation in the endosomal membrane, pH-
buﬀering eﬀect (the proton sponge eﬀect).
‘Proton- sponge’ is now the most accepted mecha-
nisms [29]. Taking full advantage of the low pH range
(pH 4.6-5.0) in endo-lysosomes, many groups focuses
on synthetic pH-responsive polymer for protein trans-
duction [30]. Endo-lysosomes are acidiﬁed by the AT-
Pase enzymes on the surface that transport protons
and counter ions from the cytoplasm into the endo-
lysosomes. The synthetic pH-responsive polymer can
combine the protons to prevent acidiﬁcation, causing
the ATPase continuing to transport more protons to
reach the desired pH. The accumulations of osmotic
pressure by counter ions ultimately trigger swelling and
rupture the endosome membrane, while releases the
polymer loading protein at the same time [31]. Yan and
his colleague report a novel delivery polymer that con-
sists of the neutral monomer (acrylamid) and degrad-
able crosslinker (acid-degradable glycerol dimethacry-
late) [32]. The endosomes staining of the cells incu-
bated with rhodamine-B-labelled horseradish peroxi-
dase (HRP) revealed co-localization of the protein with
early endosomes, with gradual escaping from endo-
lysosome to the cytoplasm. Moreover, the released
proteins can also execute their own function in cytosol
including enhanced green ﬂuorescent protein (EGFP),
sueroxide dismutase (SOD) and caspase-3 (CAS).











Stable over broad range of temperature and pH Lack of biodegradation
Slow dissolution
[23][24]
Liposome A good biocompatibility Unstable and low entrapment eﬃciency [25][26]
Nanotube Large internal volumes for drug Debatable toxicity [27]
Dendrimer Ease of modiﬁcation and size control Cytotoxicity, biocompatibility and biodistribution [28]
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Fig. 1 Steps detailing the intracellular delivery of protein drug via nanoparticle carriers. (1) endocytosis of nanoparticles;
(2) fusion of endosomes with lysosomes; (3) ‘proton-sponge’ eﬀect; (4) endosomal escape of nanoparticles; (5) degradation of
nanoparticle by lysosome; (6) exocytosis of nanoparticles.
Another mechanism of escaping from endo-lysosomes
is causing damage and fracture of the endosome mem-
brane. Amphiphilic polymers containing weakly ioniz-
able carboxyl groups and hydrophobic alkyl side chains
may response to acid environment and degrade below
their pKa ranges [33]. The degraded hydrophobic frag-
ment can bind to endosomal membrane because the
inner of membrane is hydrophobic fatty acid. Then
the additional hydrophobic fragment can interrupt the
membrane ﬂuidity, subsequently inducing membrane
lysis activity [34]. Liechty et al conﬁrmed the pheny-
lalanine derivatized polymer PP-75 have the ability of
endosomal membrane disruption [35,36]. After treat-
ment of Saos-2 cells with MBP-apoptin (a speciﬁc tu-
mor killing protein) and PP-75, 30% cells found in the
mid-apoptotic state compared with control. This result
showed the protein can release successfully from the
endo-lysosomes by the destructive hydrophobic poly-
mer [37,38].
Apart from endocytosis, nanoparticles should also
meet the various demand of organism in biocompatibil-
ity and biodistribution. The barriers should be taken
into account seriously for designing a more eﬀective for-
mulation.
Future directions
With the rapid development of molecular biology,
more and more are being understood about various pro-
teins and their roles in regulatory networks of human
health and disease. Unfortunately, delivery approach
remains to be the most signiﬁcant barrier of widespread
use in clinic of protein therapeutics. There is still a lack
of good micro- and nano-delivery systems fabricated
using micro and nanotechnology for protein available
which can overcome all the biological barriers. From
discussion above, the on-going research must consider
the following: (1) low toxicity of material; (2) nonspe-
ciﬁc activation of the immune system; (3) encapsulation
eﬃciency; (4) maintaining the nature conﬁrmation; (5)
sustained-release instead of burst release eﬀect; (6) tar-
get the diseased tissues or cells; (7) biodegradability;
(8) controlled, sustained release of therapeutics. So the
future work need focus on develop the safe and eﬀec-
tive delivery system to ensure the broadest application
of protein therapy in the clinic.
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